The Menopause Digest 07/07 - 07/13

Welcome to The Menopause Digest.

The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

The menopause conversation is graduating from symptom management to systems thinking. This week’s expert shows converge on one big idea: menopause isn’t a single hormonal event—it’s a whole-body cascade that touches bone, brain, skin, joints, and even your home office layout. Here’s what matters, why it matters now, and where the money and the medicine are heading.

The biggest strategic insight this week: estrogen decline doesn’t just cause hot flashes—it’s quietly demolishing structural tissue across the body, and the damage window is narrower than most clinicians think. On The DUTCH Podcast, researchers reframed bone loss around menopause as a 6-to-10-year “construction shutdown”—roughly three to five years before the final period to three to five years after—when osteoclasts (the demolition crew) outpace osteoblasts (the builders), and lost trabecular bone quality is nearly impossible to fully rebuild later. This is corroborated by broader bone biology research confirming that estrogen deficiency accelerates bone resorption and architectural deterioration during this transition window. The commercial and clinical implication is clear: earlier DEXA screening (age 45-50 for at-risk women) and confirming adequate estradiol exposure—not just prescribing it—should become standard practice, since a “substantial subset” of women on transdermal doses remain subtherapeutic for bone protection.pubmed.ncbi.nlm.nih+1

The same demolition-without-rebuilding story plays out in connective tissue. On Hit Play Not Pause, RMT Tara Findlay explained why frozen shoulder, plantar fasciitis, and stubborn tendinopathies spike in perimenopause: declining estrogen reduces collagen, ramps up systemic inflammation, and slows repair—turning ordinary training loads into chronic injuries. And on The Skin Real, the collagen story gets a hard number attached: women can lose up to 30% of skin collagen within five years of menopause, with sugar-driven glycation accelerating the damage. The strategic takeaway for clinicians and wellness brands alike: “estrogen decline” is no longer a niche hot-flash story—it’s the connective-tissue, skeletal, and dermatologic thread tying together three distinct but converging markets (orthopedics, aesthetics, and bone health).

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss

• FODMAP Digestive Enzymes – improves absorption and reduces GI side effects

• Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome

• Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss

• Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex – firms and smooths for youthful elasticity

• Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress

• Needle-Free Wrinkle Smoother – softens fine lines without irritation

• Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol

• Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles

• Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair

• Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck

• Even Tone Brightening Cream – evens discoloration for radiant, balanced skin

The most disruptive clinical reframe this week is that midlife mental health complaints are frequently misdiagnosed as pure hormonal fog—when the real driver is hiding in plain sight on a lab panel. Dr. Fiona Lovely’s episode on Not Your Mother’s Menopause delivered a striking data point: a psychiatry-clinic study found more than 80% of patients had undiagnosed iron deficiency anemia, and repleting iron improved anxiety, irritability, and cognition—sometimes obviating the need for psychotropics entirely. This matters because standard midlife workups often skip ferritin and B12, treating “brain fog” as a hormonal inevitability rather than a correctable deficiency.

Hello Menopause added a second twist: perimenopause doesn’t cause ADHD, it unmasks it. Fluctuating estrogen strips away the cognitive compensation strategies women have relied on for decades, suddenly exposing lifelong executive dysfunction as “new” brain fog. The commercial signal here is significant—coaching, ADHD evaluation, and multimodal care (MHT plus behavioral tools) represent an underserved intersection. Meanwhile, Menopause Mastery’s “PMOS” framework (Polyendocrine Metabolic Ovarian Syndrome) pushes the same pattern-recognition logic into metabolic health, arguing that fasting insulin, SHBG, and triglyceride/HDL ratios reveal occult insulin resistance and androgen excess years before standard glucose or total testosterone flags a problem. Across all three episodes, the throughline is identical: stop treating single symptoms in isolation and start reading the whole biological pattern.

Testosterone therapy is having a data-maturity moment, and it’s reshaping prescribing norms in real time. Dr. Heather Hirsch shared early results from a 766-woman survey showing peak satisfaction clustered at total testosterone levels of 50-80 ng/dL, while pellet therapy—prone to pushing levels to 200-300+ ng/dL—drove most of the reported side effects like acne, hirsutism, and clitoromegaly. This tracks with emerging clinical guidance favoring low-dose transdermal gels with structured monitoring over pellets, which are increasingly flagged for difficult titration and prolonged overdosing risk. The commercial implication: expect continued migration away from compounded pellets toward monitored, off-label transdermal gel protocols as more real-world data accumulates—even as formal peer-reviewed evidence remains thin.thebms+1

On the policy side, Menopause Matters, Let’s Talk flagged a genuine market-moving development: the UK is moving toward mandatory, publicly reported menopause action plans for large employers by 2027. This converts menopause support from a “nice-to-have” HR initiative into a compliance and reputational risk issue, with a portal-based accountability structure. Combined with the clinical reminder that HRT changes need a minimum 3-month evaluation window, this signals a broader trend: menopause is being institutionalized simultaneously as clinical protocol and corporate governance, and organizations that treat it as either purely medical or purely cultural will fall behind those tackling both fronts.

URL: Listen Here

This episode explores how to build menopause-friendly workplaces through culture change, inclusive education, trained line managers, and strong leadership, moving beyond checkbox policies. It also reviews the UK’s forthcoming requirement for large employers to publish transparent action plans and provides a clinical reminder that HRT changes should be assessed over at least three months. The discussion underscores that addressing psychological and sleep symptoms is crucial to retaining women in the workforce.

• Effective menopause support at work requires cultural change grounded in listening to employees and tailoring support to both individuals and specific workplace contexts; a policy plus a one-off session is not enough.

• Psychological and sleep-related symptoms (anxiety, poor concentration, insomnia/fatigue) often impair work performance more than hot flushes, contributing to women considering or leaving employment.

• Awareness for all staff and confident, trained line managers are pivotal; visible leadership endorsement, male allyship, and targeted sessions (e.g., men-only or ‘Hormones Through Life’) boost engagement and normalize conversations.

• UK employers with >250 staff are moving toward mandatory, transparent menopause/gender-equality action plans by 2027 via a public portal; plans should evidence impact and typically include policy, manager training, occupational health input, workplace adjustments, and leadership sign-off.

• Clinically, HRT remains the most effective therapy for menopausal symptoms, but any initiation, change, or cessation should be evaluated over at least 3 months to judge benefits and side effects.

When menopausal patients report work difficulties, prioritize assessment and management of psychological and sleep symptoms—not just vasomotor complaints—and set clear expectations that HRT (or any change to it) requires a minimum 3-month trial before judging effectiveness.

When starting or changing HRT, book a 12-week follow-up to reassess vasomotor, cognitive/psychological, and sleep symptoms, adjust therapy only after this interval, and offer a brief employer letter outlining reasonable workplace adjustments if needed.

URL: Listen Here

This episode emphasizes reassessing bone health around the menopausal transition, highlighting that estrogen decline drives rapid trabecular bone loss and that prevention—via earlier DEXA screening, family-history–based risk assessment, and timely, adequately dosed hormone therapy—is more effective than late pharmacologic rescue. The discussion also underscores variability in estradiol absorption across delivery routes, supporting selective hormone-level monitoring to ensure bone-protective exposure. Limitation: several studies were discussed anecdotally without full citation details in the transcript.

• The most rapid and consequential bone loss occurs from roughly 3–5 years before to 3–5 years after the final menses; estrogen decline during perimenopause disrupts bone remodeling (↑osteoclast activity, ↓osteoblast activity), making timing of intervention critical.

• Baseline DEXA should be considered earlier than standard guidelines (e.g., around age 45–50 for at-risk women) to establish trajectory; family history is a strong predictor, and site-specific loss (spine vs hip) guides risk and management.

• Bone quality (trabecular architecture), not just density, determines fragility—vertebral compression fractures are highly morbid; prevention is superior as lost quality is difficult to fully restore.

• Estradiol exposure on menopausal hormone therapy varies by delivery route and individual absorption; a substantial subset on standard transdermal doses remain subtherapeutic, supporting selective hormone level monitoring and dose/route adjustment for bone protection.

• Gaps in primary care access and continuity contribute to under-screening and undertreatment; proactive, relationship-based preventive care and patient education are essential to reduce osteoporotic fractures.

Early risk stratification and intervention during perimenopause—combining family-history–driven early DEXA baselining with timely, adequately dosed menopausal hormone therapy when appropriate—can preserve trabecular bone quality that is difficult to rebuild later.

For women aged 45–55 with osteoporosis risk (e.g., positive family history), order a baseline DEXA now and, if starting estrogen therapy for bone protection, confirm adequate estradiol exposure (approx. 60–160 pg/mL target in serum for building/preserving bone) using appropriate testing by route (mid-patch serum for transdermal; multi-point urine for gels/troches), then titrate dose/route accordingly.

URL: Listen Here

This episode links mental health changes at perimenopause/menopause to underdiagnosed iron deficiency (and B12 deficiency), urging clinicians to assess and correct these before relying solely on psychotropics. The host underscores a research and practice gap in midlife women, noting that appropriate iron repletion can meaningfully improve mood, anxiety, sleep, cognition, and post-concussion recovery.

• Iron deficiency (including low ferritin) and B12 deficiency are common, under-recognized contributors to anxiety, depression, sleep disturbance, cognitive issues, and poor TBI/concussion recovery in perimenopausal and menopausal women.

• Evaluate iron status (CBC, ferritin, iron studies) and B12 when midlife patients present with new or worsening mental health symptoms; inadequate oxygen delivery from anemia can undermine psychotherapy and psychotropics.

• Risk factors for iron deficiency include menstruation, pregnancy/postpartum blood loss, vegetarian/low-iron diets, frequent blood donation, and celiac disease; many women enter perimenopause still iron-deficient from prior pregnancies.

• A small psychiatry-clinic study referenced by the host found >80% of patients had iron deficiency anemia, and iron repletion improved hyperemotivity, anxiety, irritability, depressive symptoms, restless legs, eating disorders, and cognition.

• Research on iron deficiency and mental health in midlife women is sparse (most literature focuses on pregnancy), highlighting a care and evidence gap; test before supplementing and replete iron appropriately if deficient.

In midlife women with mood, anxiety, sleep, or cognitive complaints, screen for and correct iron deficiency (ferritin-based iron studies) and B12 deficiency before or alongside initiating psychotropic therapy, as restoring oxygen delivery can significantly improve neuropsychiatric symptoms.

For perimenopausal/menopausal patients with new mental health symptoms, order CBC, ferritin, serum iron, TIBC/transferrin saturation, and vitamin B12 (consider folate). If iron deficiency anemia is confirmed, initiate iron repletion per local guidelines and dietary counseling, and recheck labs in 6–8 weeks before escalating psychotropics.

URL: Listen Here

This episode clarifies that perimenopause can unmask rather than cause ADHD, explaining why many women first experience significant executive dysfunction at midlife. It offers practical behavioral strategies and supports a multimodal approach (hormonal, pharmacologic, behavioral, and mindfulness-based) to restore daily functioning and emotional well-being. Note: Content reflects a coaching perspective; no formal studies were cited and minor transcript errors are present.

• Perimenopause does not cause ADHD; fluctuating estrogen during perimenopause can unmask or amplify pre-existing ADHD symptoms, especially executive dysfunction.

• Executive function challenges—planning, initiation, organization, time blindness, and emotional regulation—often intensify at midlife, leading to overwhelm, shame, and impostor feelings.

• Prioritizing the important over the merely interesting is critical; practical tools include planning ahead, using a single-notebook system, setting a daily “top 3” list, and breaking tasks into smaller steps.

• Emotional regulation strategies—pausing before responding, checking for intent, asking clarifying questions, reframing self-talk, and granting self-grace—reduce reactivity and support functioning.

• Multimodal, individualized care (e.g., MHT/HRT when appropriate, sleep support such as hydroxyzine, ADHD medications, coaching/therapy, mindfulness/yoga/yoga nidra/hot yoga) can restore function and well-being.

In midlife patients presenting with new-onset brain fog, inattention, disorganization, or time blindness, consider that perimenopausal hormone fluctuations may be unmasking a lifelong (previously compensated) ADHD, and tailor evaluation and management accordingly.

Add a brief screen for lifelong ADHD traits (childhood disorganization, losing items, time blindness, task initiation problems) alongside a perimenopause symptom review in women 40–55 with cognitive complaints; if both are present, discuss/consider MHT when appropriate, refer for ADHD evaluation, and introduce a single-notebook plus daily “top 3” task routine.

URL: Listen Here

This episode explores why musculoskeletal pain and stubborn tendinopathies surge during perimenopause and menopause, highlighting estrogen-related collagen loss, pro‑inflammatory shifts, and slower tendon repair as key drivers. It offers practical strategies—massage, mobility, eccentric loading, flexible training splits, and stress/sleep optimization—plus early recognition of frozen shoulder and consideration of HRT, to help clinicians and active women maintain performance and reduce injury risk.

• Perimenopausal hormonal changes—especially declining estrogen—reduce collagen, increase systemic inflammation, and slow tendon/muscle repair, raising risk for frozen shoulder, plantar fasciitis, gluteal tendinopathy, and other persistent MSK pains.

• Many midlife “overuse” injuries are better understood as load–capacity and recovery mismatches; adapting training (more recovery, flexible splits), prioritizing sleep/stress, and graded loading are essential.

• Eccentric loading (and isometrics) is a cornerstone for tendon rehab; using simple, frequent “movement snacks” and a green/yellow/red pain framework improves adherence and safe progression.

• Massage therapy can meaningfully support this phase by enhancing parasympathetic tone, reducing pain sensitivity, improving mobility, and offering time‑rich, validating, perimenopause‑informed care.

• Frozen shoulder is common, often atraumatic, worse at night, and likely linked to systemic inflammation in midlife; early evaluation and rehab are key, and emerging data suggest hormone therapy may reduce incidence.

In active midlife women, musculoskeletal complaints frequently reflect perimenopause-driven connective tissue and inflammatory shifts; reframing these issues as capacity and recovery problems—and treating through a perimenopause‑informed lens—improves outcomes more than focusing solely on local ‘overuse.’

For any midlife woman presenting with atraumatic shoulder stiffness or recalcitrant tendinopathy, screen for perimenopause and systemic contributors (sleep, thyroid, autoimmune/inflammatory load), initiate a home program of daily eccentric ‘movement snacks’ progressed within green/yellow/red pain zones, prioritize sleep and stress reduction, and discuss/referral for hormone therapy when clinically appropriate alongside perimenopause‑informed PT/massage care.

URL: Listen Here

This episode explains what postpartum psychosis is, how to recognize it early, and why it requires urgent treatment. The hosts and survivor-advocates emphasize rapid inpatient management (antipsychotic plus lithium, sleep restoration), proactive education and planning for all families, and comprehensive recovery supports that often lead to meaningful post‑traumatic growth.

• Postpartum psychosis (PPP) is the most severe perinatal psychiatric illness, marked by psychosis (delusions, hallucinations), disorganized or agitated behavior, and mood symptoms that can wax and wane—and it is a medical emergency.

• Timely inpatient treatment with antipsychotics (often augmented with lithium), rapid sleep restoration (including sedating agents/benzodiazepines when needed), and early family involvement leads to excellent recovery.

• Profound sleep deprivation is a common precipitant and early warning sign; proactively protecting maternal sleep is central to prevention, stabilization, and recovery.

• Risk factors include personal/family history of bipolar disorder or postpartum psychosis, preeclampsia (≈3–4× increased risk), traumatic birth, and prior trauma—but PPP can occur after any birth.

• Recovery is typically robust and can include significant post‑traumatic growth; multidisciplinary supports (medication, psychotherapy such as EMDR, peer groups, and self‑care) are key.

Postpartum psychosis should be managed as a psychiatric emergency; early inpatient care with an antipsychotic plus lithium and aggressive sleep restoration markedly improves outcomes and enables rapid return to safe parenting.

Implement a universal prenatal postpartum mental health emergency plan by the mid‑pregnancy visit: document personal/family psychiatric history and risk factors, establish a postpartum sleep‑protection and backup caregiver plan, provide crisis contacts (988; National Maternal Mental Health Hotline 1‑833‑TLC‑MAMA), and identify local perinatal psychiatric resources (e.g., PSI programs, specialized inpatient units).

URL: Listen Here

This episode reframes PCOS as PMOS, a multi-system metabolic–hormonal syndrome often missed in midlife, and teaches clinicians how to read lab patterns rather than isolated values. It details phenotype-specific markers and interventions that can improve metabolic control, androgen excess symptoms, sleep, mood, and long-term cardiometabolic risk during the peri- to postmenopausal transition.

• PMOS (Polyendocrine Metabolic Ovarian Syndrome) is broader than classic PCOS and is frequently missed—especially in women with regular periods or without ovarian cysts—so diagnosis relies on pattern recognition across labs rather than a single value.

• Early insulin resistance is central: fasting insulin and HOMA-IR identify problems long before glucose or A1c rise; triglycerides and the triglyceride/HDL ratio are highly informative, often preceding overt glycemic changes.

• Androgen assessment must go beyond total testosterone: check SHBG, free androgen index (FAI), DHEA-S, DHT, and other androgens (e.g., androstenedione); low SHBG (<40) increases biologically active androgens and can drive acne, hair loss, and hirsutism even when total T is “normal.”

• Perimenopause obscures classic reproductive markers (LH/FSH, estradiol, progesterone); luteal-phase and follicular-phase defects can exist despite apparent cycling, and thyroid T3 conversion can be impaired by insulin resistance and inflammation.

• Three dominant PMOS phenotypes guide treatment: (1) insulin-driven, (2) adrenal-driven (HPA axis/cortisol), and (3) inflammatory/gut-driven; targeted management includes high-fiber nutrition, resistance and Zone 2 training, modest time-restricted eating (12–14 hours), vitamin D and magnesium repletion, inositol/berberine/ALA for insulin sensitivity, gut support (e.g., calcium-D-glucarate for high beta-glucuronidase), and judicious hormone therapy.

For perimenopausal and menopausal patients with suspected PMOS, a pattern-based lab approach—anchored by fasting insulin/HOMA-IR, SHBG/free-androgen metrics, triglyceride/HDL ratio, and inflammatory and nutrient markers—more reliably reveals the underlying phenotype and should guide targeted, phenotype-specific interventions.

At the next lab draw, add fasting insulin and SHBG to your standard panel, then calculate HOMA-IR and the free androgen index (FAI = total testosterone/SHBG × 100) to screen for occult PMOS and classify the likely phenotype before tailoring therapy.

URL: Listen Here

This episode explains why GLP-1s work when diets don’t by highlighting metabolic derangements in obesity and the role of GLP-1/GIP medications in restoring physiologic satiety and enabling sustainable behavior change. It reframes exercise as essential for maintenance and health, outlines a multi-pillar care model, and addresses real-world access barriers (off-label legality, step therapy, prior authorizations) and safety concerns.

• GLP-1/GIP therapies address core metabolic dysfunction in obesity (e.g., insulin resistance, dysregulated hunger/satiety), explaining why “eat less, move more” often fails as a standalone strategy.

• Exercise is vital for weight maintenance, body composition, cardiovascular and mental health, but is not the primary driver of clinically significant weight loss; medications can reduce food noise and make sustainable habits feasible.

• Effective obesity care is multi-pillar: nutrition, movement, behavioral health (stress/sleep), medications, and surgery—tailored to the individual; building non-food coping (hobbies, community) is protective.

• Insurance/PBM barriers are increasing (step therapy, frequent/repeat prior authorizations, diagnosis verification), yet off-label prescribing is legal; appeals are underused (<1% filed) despite high success rates (>60% approvals).

• Safety first: avoid non-reputable compounded products and med-spa injections; partner with obesity-medicine clinicians or reputable telehealth programs for evidence-based care and access support.

Obesity is a chronic, biologically mediated disease in which hormonal signaling and energy regulation are disrupted; GLP-1/GIP agonists can correct satiety/hunger pathways and insulin resistance, while exercise should be framed primarily for maintenance and cardiometabolic/mental health—not acute weight loss—within a personalized, multi-pillar treatment plan.

Screen and document comorbidities (e.g., A1c ≥6.5% for type 2 diabetes, PCOS, sleep/stress issues), then integrate anti-obesity pharmacotherapy (e.g., GLP-1/GIP agonists) with close follow-up for dose titration and explicit counseling that movement supports maintenance; proactively prepare for step therapy/PA requirements (and file timely appeals) or coordinate referral to an obesity-medicine specialist/telehealth program.

URL: Listen Here

Dr. Anna Cabeca interviews feng shui expert Marie Diamond on how home environment and spatial cues can affect stress, sleep, hormones, and overall well-being. The episode offers practical, non-pharmacologic adjustments—especially in the bedroom and workspace—to promote calmer neurophysiology and support patients navigating perimenopause/menopause and chronic stress.

• The physical arrangement and symbolism of the home can influence stress physiology, sleep quality, relationships, and perceived success; feng shui provides a structured way to optimize these environmental factors.

• Bedroom hygiene is central: reduce clutter (including under the bed), avoid mirrors/TVs reflecting the bed, close the bathroom door at night, and avoid excessive red (fire) or all-blue (water) color schemes to support calmer sleep and lower stress.

• Positioning to see the door (both in bedroom and workspace) is associated with calmer brain states (more alpha, less beta activity) and a greater sense of safety; sitting with one’s back to the door may heighten arousal and cortisol.

• Clutter elevates stress and conflict; practical strategies include using a ‘declutter buddy,’ a five-bag system (keep, trash, give to friend, donate, sell), and visually separating work from leisure areas with screens or covers.

• Directional practices (via the Marie Diamond app) suggest facing or activating specific compass directions for success, health, relationships, and wisdom; anecdotal examples include improved organization, mood, and perceived opportunity after reorientation.

Simple, low-risk environmental modifications—particularly in the bedroom (remove or cover mirrors/TVs reflecting the bed, close the bathroom door, minimize clutter, and position the bed to see the door)—may reduce arousal, improve sleep, and potentially lower stress-related physiologic burden in midlife patients with hormonal symptoms, insomnia, or hypertension.

Incorporate an environmental sleep-hygiene check at visits: advise patients to declutter the bedroom (including under the bed), close the bathroom door at night, and remove/cover any mirrors or TV screens reflecting the bed for a 2-week trial, then reassess sleep quality, blood pressure, and daytime stress.

URL: Listen Here

Dr. Hirsch shares early findings from a 766-person survey on testosterone use in menopause, noting that many women feel best around 50–80 ng/dL and that supraphysiologic exposure—often seen with pellets—is linked to more adverse effects. The episode emphasizes preference for transdermal gels at one-tenth male dosing, routine monitoring, and clinician-guided, individualized titration, with acknowledgment that the dataset is raw, non–peer reviewed, and subject to selection bias.

• This episode reports raw, unpublished survey data from 766 women (social-media recruited; selection bias acknowledged) about testosterone use in peri/postmenopause.

• Highest satisfaction clustered when total testosterone was approximately 50–80 ng/dL; dissatisfaction was common when levels were <25 ng/dL and also when >125 ng/dL, with pellets often producing sustained supraphysiologic levels (200–300+ ng/dL) and more side effects.

• Knowledge gaps and testing practices vary: ~31% did not know their testosterone level, 10% were told it was “normal” without a value, and 6% had never been measured—highlighting the need for transparent lab review and shared decision-making.

• Respondents preferred commercial male transdermal gels (e.g., Testim, Androgel) used at ~one-tenth the male dose over compounded options; pellets were discouraged due to difficulty titrating and risk of prolonged high levels; injections may be considered only after topical trials.

• Reported benefits extended beyond libido to include improved brain fog, mood, and joint pain; key risks of high exposure include acne, hirsutism, scalp hair loss, voice deepening and clitoromegaly (potentially permanent), and metabolic/liver abnormalities—supporting the need for level monitoring (baseline, 8–10 weeks, 6 months, annually).

Symptom-guided, carefully monitored use of transdermal male testosterone gels (titrated to a physiologic female range and avoiding sustained supraphysiologic levels) can deliver meaningful benefits while minimizing androgenic and metabolic harms; pellet therapy should generally be avoided due to prolonged, hard-to-reverse overdosing.

When initiating off-label testosterone in a postmenopausal patient, obtain a baseline total testosterone (consider SHBG if response is suboptimal), start with a transdermal gel at ~1/10 the male dose, reassess symptoms and recheck levels at 8–10 weeks (then at 6 months and annually), titrating to symptom relief while keeping total testosterone generally below ~100–125 ng/dL; avoid pellets.

URL: Listen Here

This episode explains the biology of accelerated collagen loss during peri‑ and post‑menopause, emphasizing that estrogen decline drives faster collagen degradation and reduced synthesis. It highlights a proactive, nutrition‑first strategy—adequate protein and vitamin C, reduced added sugar, anti‑inflammatory fats, antioxidants, and hydration—and reviews the mixed but possible benefits of hydrolyzed collagen supplements, urging clinicians to counsel patients before and during the midlife transition.

• Women can lose up to 30% of skin collagen within five years after menopause; collagen declines ~1% per year from the mid‑20s and accelerates with the estrogen drop at menopause.

• Estrogen loss reduces collagen synthesis and increases degradation, leading to thinner, less firm, rough/‘crepey’ skin—necessitating skincare and lifestyle adjustments across life stages.

• Nutrition is foundational for collagen: adequate dietary protein plus vitamin C are required for collagen synthesis; the speaker suggests roughly 1 g protein per pound of ideal body weight and prioritizing protein early in the day.

• High sugar intake accelerates skin aging via glycation (AGEs) and systemic inflammation; cutting sugar‑sweetened beverages can make a rapid, meaningful impact.

• Oral hydrolyzed collagen (type I) has mixed but potentially positive evidence for skin hydration and thickness after ~8 weeks; supplements are animal-derived and may be tried, but whole‑food protein likely moves the needle more.

Rapid, estrogen-driven collagen loss around menopause is substantial; proactive, inside‑out management—especially optimizing protein intake and minimizing added sugar to reduce glycation—can help preserve skin structure and should be part of routine counseling for midlife women.

Advise patients to eliminate sugar‑sweetened beverages and replace them with water or unsweetened options for at least 8 weeks to reduce glycation and inflammation that accelerate collagen loss.

URL: Listen Here

This episode explains reproductive and hormonal strategies to prevent epithelial ovarian cancer by minimizing lifetime ovulatory cycles. It compares the protective effects of pregnancy, breastfeeding, and especially combined estrogen–progestin contraception, and notes uncertainty around HRT, guiding clinicians to frame prevention around ovulation suppression.

• Lifetime number of ovulatory cycles (“menstrual life”) is a key driver of epithelial ovarian cancer risk; fewer cycles lower risk.

• Pregnancy and breastfeeding reduce risk by suppressing ovulation; breastfeeding adds roughly 18–34% risk reduction depending on duration per child.

• Combined estrogen–progestin contraception (pill/patch/ring) substantially reduces risk by inhibiting ovulation (~10% reduction per 5–7 years of use; cumulative ~40–56% with long-term use), with protection persisting up to 35 years after discontinuation; speaker cites a decrease in lifetime risk from ~1.4% to ~0.3%.

• Among nonsurgical options, long-term combined hormonal contraception offers the greatest risk reduction; surgical bilateral salpingo-oophorectomy provides the largest overall reduction (~90%) but is outside routine prevention for average-risk women.

• Postmenopausal hormone therapy (HRT) is portrayed as an uncertain and likely minimal risk factor; the episode emphasizes that ovulatory cycling—rather than hormones per se—is the principal concern.

Inhibiting ovulation is the most impactful modifiable mechanism to lower epithelial ovarian cancer risk; long-term combined estrogen–progestin contraception provides substantial, durable protection even for average-risk patients.

During contraceptive counseling for appropriate pre/perimenopausal patients, estimate their menstrual life and discuss prescribing a combined estrogen–progestin method to suppress ovulation, explicitly explaining the associated long-term ovarian cancer risk reduction and confirming absence of contraindications.

Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:

Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website

Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:

Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.

Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.

It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.

👉 Deploy your Medical AI Chatbot today and take control of your health narrative

Managing menopause isn’t about “getting through it”—it’s about doing it strategically. The Menopause Premium Program is a 16-week, high-touch protocol designed for high-performing women who demand more than quick fixes. With board-certified specialists, evidence-based hormone and non-hormonal options, and proactive risk reduction, this program helps restore clarity, stabilize sleep, and safeguard long-term health. If brain fog, disrupted nights, or unpredictable weight shifts are holding you back, this is your opportunity to take control with the same precision you bring to your career.

👉Discover the Menopause Premium Program